Haemonetics (HAE) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Haemonetics (HAE) stock.

Latest Upgrades and Downgrades for Haemonetics Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Jefferies	Young Li	Initiate	Buy	$150
—	Citigroup	Joanne Wuensch	PT Raise	Buy	$123→$149
—	Barrington Research	Michael Petusky	PT Raise	Outperform	$140→$145
—	BTIG	Marie Thibault	PT Raise	Buy	$130→$142
—	Barrington Research	Michael Petusky	PT Raise	Outperform	$118→$140
—	Mizuho	Anthony Petrone	PT Raise	Outperform	$95→$140
—	BTIG	Marie Thibault	PT Raise	Buy	$110→$130
—	Citigroup	Joanne Wuensch	Upgrade	Neutral→Buy	$92→$123
—	Raymond James	Andrew Cooper	PT Raise	Outperform	$105→$125
—	Baird	David Rescott	PT Raise	Outperform	$96→$119
—	Barrington Research	Michael Petusky	PT Raise	Outperform	$95→$118
—	BTIG	Marie Thibault	PT Raise	Buy	$96→$110
—	Citigroup	Joanne Wuensch	PT Raise	Neutral	$79→$92
—	JP Morgan	Allen Gong	PT Raise	Neutral	$62→$86
—	BTIG	Marie Thibault	PT Raise	Buy	$84→$96
—	Mizuho	Anthony Petrone	PT Raise	Outperform	$85→$90
—	BTIG	Marie Thibault	Maintained	Buy	$84
—	BTIG	Marie Thibault	Maintained	Buy	$84
—	Mizuho	Anthony Petrone	PT Raise	Outperform	$70→$85
—	Citigroup	Joanne Wuensch	PT Raise	Neutral	$64→$70

Analyst Ratings News

PRO
Jefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150

Jefferies analyst Young Li initiates coverage on Haemonetics (NYSE:HAE) with a Buy rating and announces Price Target of $150.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $123 to $149.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $140 to $145.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Haemonetics, Raises Price Target to $142

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $130 to $142.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.

Benzinga Newsdesk

Haemonetics Corp

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Haemonetics (HAE) Stock Price Target 2026

Latest Upgrades and Downgrades for Haemonetics Stock

Haemonetics (HAE) Stock Price Target 2026

Latest Upgrades and Downgrades for Haemonetics Stock

Analyst Ratings News

PRO
Jefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150

PRO
Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145

PRO
BTIG Maintains Buy on Haemonetics, Raises Price Target to $142

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Jefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150

PRO
Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145

PRO
BTIG Maintains Buy on Haemonetics, Raises Price Target to $142

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

Haemonetics Corp

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Haemonetics (HAE) Stock Price Target 2026

Latest Upgrades and Downgrades for Haemonetics Stock

Haemonetics (HAE) Stock Price Target 2026

Latest Upgrades and Downgrades for Haemonetics Stock

Analyst Ratings News

PROJefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150

PROCitigroup Maintains Buy on Haemonetics, Raises Price Target to $149

PROBarrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145

PROBTIG Maintains Buy on Haemonetics, Raises Price Target to $142

PROBarrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

PROMizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

People Also Watch

People Also Watch

Analyst Ratings News

PROJefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150

PROCitigroup Maintains Buy on Haemonetics, Raises Price Target to $149

PROBarrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145

PROBTIG Maintains Buy on Haemonetics, Raises Price Target to $142

PROBarrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

PROMizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
Jefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150

PRO
Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145

PRO
BTIG Maintains Buy on Haemonetics, Raises Price Target to $142

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
Jefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150

PRO
Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145

PRO
BTIG Maintains Buy on Haemonetics, Raises Price Target to $142

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140